Search research articles
Contact Us
Filters
Showing results (121-130 of 222) with videos related to
Page
of 23
Sort By:
Molecular and Cellular Biology
|
August 18, 2004
Jun blockade of erythropoiesis: role for repression of GATA-1 by HERP2
Kamaleldin E Elagib, Mang Xiao, Isa M Hussaini, et al.
Cancer Biology & Therapy
|
July 26, 2011
Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment
Andrea R Hagemann, Mark Cadungog, Ian S Hagemann, et al.
Cancer Genetics and Cytogenetics
|
December 2, 2004
Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform
Hiroshi Tsuda, Michael J Birrer, Yoichi M Ito, et al.
Molecular Cancer Therapeutics
|
February 3, 2016
Targeting the Nuclear Import Receptor Kpnβ1 as an Anticancer Therapeutic
Pauline J van der Watt, Alicia Chi, Tamara Stelma, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 27, 2013
Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer
Jose Alejandro Rauh-Hain, Stephanie H Guseh, Katharine M Esselen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2018
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine
Ursula A Matulonis, Michael J Birrer, David M O'Malley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer
Michael J Callahan, Zoltan Nagymanyoki, Tomas Bonome, et al.
Gynecologic Oncology
|
July 10, 2021
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
Carolyn N Krasner, Susana M Campos, Chantay L Young, et al.
Gynecologic Oncology
|
October 16, 2022
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial
John H Farley, William E Brady, David O'Malley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2005
Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers
Amir A Jazaeri, Christopher S Awtrey, Gadisetti V R Chandramouli, et al.
Page
of 23
Search research articles
Search
Showing results (121-130 of 222) with videos related to
Sort By:
Page
of 23
Molecular and Cellular Biology
|
August 18, 2004
Jun blockade of erythropoiesis: role for repression of GATA-1 by HERP2
Kamaleldin E Elagib, Mang Xiao, Isa M Hussaini, et al.
Cancer Biology & Therapy
|
July 26, 2011
Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment
Andrea R Hagemann, Mark Cadungog, Ian S Hagemann, et al.
Cancer Genetics and Cytogenetics
|
December 2, 2004
Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform
Hiroshi Tsuda, Michael J Birrer, Yoichi M Ito, et al.
Molecular Cancer Therapeutics
|
February 3, 2016
Targeting the Nuclear Import Receptor Kpnβ1 as an Anticancer Therapeutic
Pauline J van der Watt, Alicia Chi, Tamara Stelma, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 27, 2013
Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer
Jose Alejandro Rauh-Hain, Stephanie H Guseh, Katharine M Esselen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2018
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine
Ursula A Matulonis, Michael J Birrer, David M O'Malley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer
Michael J Callahan, Zoltan Nagymanyoki, Tomas Bonome, et al.
Gynecologic Oncology
|
July 10, 2021
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
Carolyn N Krasner, Susana M Campos, Chantay L Young, et al.
Gynecologic Oncology
|
October 16, 2022
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial
John H Farley, William E Brady, David O'Malley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2005
Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers
Amir A Jazaeri, Christopher S Awtrey, Gadisetti V R Chandramouli, et al.
Page
of 23